NFKB1 and B-cell non-Hodgkin lymphoma: A recent study showed that, in B cell lymphomas, decitabine repressed B cell-specific gene transcription and activated NF-κB signalling; during osteoclastogenesis, decitabine conversely inhibited the activity of NF-κB, AP-1 and extracellular signal-regulated kinase (ERK) but not the PI3K/Akt pathway [29].